Question-based Drug Development for psilocybin - Authors' reply.
Carhart-Harris RL, Nutt DJ.
Lancet Psychiatry · letter · DOI 10.1016/s2215-0366(16)30217-6 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för psilocybin. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
51 träffarPsilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ.
Lancet Psychiatry · clinical trial; journal article · DOI 10.1016/s2215-0366(16)30065-7Enhanced repertoire of brain dynamical states during the psychedelic experience.
Tagliazucchi E, Carhart-Harris R, Leech R, Nutt D, Chialvo DR.
Hum Brain Mapp · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/hbm.22562The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers.
Roseman L, Leech R, Feilding A, Nutt DJ, Carhart-Harris RL.
Front Hum Neurosci · research-article; journal article · DOI 10.3389/fnhum.2014.00204The effect of psilocin on memory acquisition, retrieval, and consolidation in the rat.
Rambousek L, Palenicek T, Vales K, Stuchlik A.
Front Behav Neurosci · research-article; journal article · DOI 10.3389/fnbeh.2014.00180Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.
Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX.
Biol Psychiatry · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/j.biopsych.2014.04.010Potential therapeutic effects of psilocybin/psilocin are minimized while possible adverse reactions are overrated.
dos Santos RG.
Ther Drug Monit · letter; comment · DOI 10.1097/ftd.0000000000000028Psilocybin--summary of knowledge and new perspectives.
Tylš F, Páleníček T, Horáček J.
Eur Neuropsychopharmacol · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.euroneuro.2013.12.006[The impact of psilocybin on visual perception and spatial orientation--neuropsychological approach].
Jastrzebski M, Bala A.
Psychiatr Pol · review; journal articleSpatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin.
Bernasconi F, Schmidt A, Pokorny T, Kometer M, Seifritz E, Vollenweider FX.
Cereb Cortex · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1093/cercor/bht178Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations.
Kometer M, Schmidt A, Jäncke L, Vollenweider FX.
J Neurosci · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1523/jneurosci.3007-12.2013Evolution of the toxins muscarine and psilocybin in a family of mushroom-forming fungi.
Kosentka P, Sprague SL, Ryberg M, Gartz J, May AL, Campagna SR, Matheny PB.
PLoS One · research support, non-u.s. gov't; research-article; review; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1371/journal.pone.0064646Peak experiences of psilocybin users and non-users.
Cummins C, Lyke J.
J Psychoactive Drugs · journal article · DOI 10.1080/02791072.2013.785855Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin.
Young SN.
J Psychiatry Neurosci · article-commentary; review; journal article · DOI 10.1503/jpn.120128Studying the effects of classic hallucinogens in the treatment of alcoholism: rationale, methodology, and current research with psilocybin.
Bogenschutz MP.
Curr Drug Abuse Rev · research support, non-u.s. gov't; review; journal article · DOI 10.2174/15733998113099990002Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis.
Carhart-Harris RL, Leech R, Erritzoe D, Williams TM, Stone JM, Evans J, Sharp DJ, Feilding A, Wise RG, Nutt DJ.
Schizophr Bull · research support, non-u.s. gov't; research-article; journal article · DOI 10.1093/schbul/sbs117Magic truffles or Philosopher's stones: a legal way to sell psilocybin?
Pellegrini M, Rotolo MC, Marchei E, Pacifici R, Saggio F, Pichini S.
Drug Test Anal · evaluation study; journal article · DOI 10.1002/dta.1400The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions.
Schmidt A, Kometer M, Bachmann R, Seifritz E, Vollenweider F.
Psychopharmacology (Berl) · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1007/s00213-012-2811-0Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans.
Carter OL, Hasler F, Pettigrew JD, Wallis GM, Liu GB, Vollenweider FX.
Psychopharmacology (Berl) · research support, non-u.s. gov't; journal article · DOI 10.1007/s00213-007-0930-9The pharmacology of psilocybin.
Passie T, Seifert J, Schneider U, Emrich HM.
Addict Biol · review; journal article · DOI 10.1080/1355621021000005937Experimental psychiatry. V. Psilocybine, a new psychotogenic drug.
RINKEL M, ATWELL CR, DIMASCIO A, BROWN J.
N Engl J Med · journal article · DOI 10.1056/nejm196002112620606